Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database
Aslihan Avanoglu-Guler(Vita-Salute San Raffaele University), EUSTAR Collaborators, Luca Idolazzi(University of Verona), Nicoletta Del Papa(University of Milan), Emmanuel Chatelus(Laboratoire National de Référence), Anna Wojteczek(Gdańsk Medical University), Marie Elise Truchetet(Centre National de la Recherche Scientifique), Ulf Müller-Ladner, Alexandra Balbir-Gurman, Michael Hughes, Petros P Sfikakis, Oliver Distler, Francesco Del Galdo, Madelon C Vonk, Marco Matucci-Cerinic, Corrado Campochiaro, Silvia Bellando Randone, Giacomo De Luca, David Launay, Simona Rednic(Charité - Universitätsmedizin Berlin), Lorenzo Dagna, Liala Moschetti(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia)
Cited by 0
Related Papers
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β<sub>2</sub>‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β<sub>2</sub>‐Glycoprotein I and Induce Endothelial Activation
|Arthritis & Rheumatism|1997|290
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207